---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040248"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T17:27:21.383176+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FibroGen gets Nasdaq delisting notice; appeals; reports Q4 loss of $8.7M, China sale to AstraZeneca

## Summary
- Nasdaq notified FibroGen on March 12, 2025 that it failed to regain $1.00 minimum bid price; delisting stayed after March 14 appeal; hearing pending.
- Q4 2024 revenue from continuing ops $3.1M (vs $3.6M Q4 2023); net loss $8.7M ($0.08 loss per share) vs $62.5M ($0.63) prior year.
- Full year 2024 net loss from continuing ops $153.1M ($1.53 loss/share) vs $323.0M ($3.32) in 2023; total cash $121.1M at year-end.
- Announced sale of FibroGen China to AstraZeneca for ~$160M; expected close by mid-2025; proceeds to repay term loan, extend cash runway into 2027.
- Upcoming milestones: Phase 2 monotherapy trial of FG-3246 in mCRPC start by mid-2025; topline combo study results 2H 2025; FDA meeting for roxadustat in LR-MDS in Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-040248
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/0000950170-25-040248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/fgen-20250312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040248
- JSON: https://secwatch.observer/filing/0000950170-25-040248.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040248.txt

## Key facts
- Listing & Compliance Notices
  KYNTRA BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: September 12, 2024, FibroGen received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market notifying FibroGen that for 30 consecutive business days the bid price of FibroGen’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1) (the “Rule”). Therefore, in accordance with the Nasdaq listing rules, FibroGen was provided 180 calendar days, or until March 11, 2025 to regain compliance with the minimum bid price rule. On March 12, 2025, FibroGen received written noti
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/0000950170-25-040248-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.